SecProbe.io

Filing text and metadata
Intelligence Terminal Search Probe Scores Topics IPO Watchlist Monthly Activity About API

SEC Comment Letter for Nkarta, Inc. (NKTX) (CIK 0001787400) (NKTX) — Mar 31, 2026

Nkarta, Inc. (NKTX) (CIK 0001787400)
Date: March 31, 2026 · CIK: 0001787400 · Accession: 0000000000-26-003267

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 333-294611

Date
March 31, 2026
Author
Division of
Form
UPLOAD
Company
Nkarta, Inc. (NKTX) (CIK 0001787400)

Letter

Re: Nkarta, Inc. Registration Statement on Form S-3 Filed March 25, 2026 File No. 333-294611 Dear Paul Hasting:

March 31, 2026

Paul Hasting Chief Executive Officer Nkarta, Inc. 1150 Veterans Boulevard South San Francisco, CA 94080

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Doris Stacey Gama at 202-551-3188 with any questions.

Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Brandon N. Wachs

Show Raw Text
<DOCUMENT>
<TYPE>TEXT-EXTRACT
<SEQUENCE>2
<FILENAME>filename2.txt
<TEXT>
 March 31, 2026

Paul Hasting
Chief Executive Officer
Nkarta, Inc.
1150 Veterans Boulevard
South San Francisco, CA 94080

 Re: Nkarta, Inc.
 Registration Statement on Form S-3
 Filed March 25, 2026
 File No. 333-294611
Dear Paul Hasting:

 This is to advise you that we have not reviewed and will not review your
registration
statement.

 Please refer to Rules 460 and 461 regarding requests for acceleration.
We remind you
that the company and its management are responsible for the accuracy and
adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action
by the staff.

 Please contact Doris Stacey Gama at 202-551-3188 with any questions.

 Sincerely,

 Division of
Corporation Finance
 Office of Life
Sciences
cc: Brandon N. Wachs
</TEXT>
</DOCUMENT>